[Abstract Only] Randomized Trial: Olanzapine Plus Standard Antiemetic Therapy for the Prevention of Chemotherapy-induced Nausea and Vomiting
8 Jan, 2020 | 22:12h | UTCOlanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Related Commentary on Twitter
in phase III trial, patients received anti-emetic combination plus placebo or 5 mg olanzapine (dose lower than standard to avoid somnolence); 5 mg dose was deemed effective https://t.co/urEz3AKFdA
— NatureRevClinOncol (@NatRevClinOncol) December 19, 2019